Chemotherapy-Induced Nausea and Vomiting (CINV): A Comprehensive Prevention and Management Guideline

Evidence-based guideline for emetogenic risk classification, antiemetic regimen selection, and management of chemotherapy-induced nausea and vomiting.

4 articles • Updated Mar 2026

CINV Guideline — Part 4: Assessment Tools, Non-Pharmacological Interventions, and Guideline Implementation

Patient assessment and grading tools for CINV including CTCAE and MASCC Antiemesis Tool, evidence-based non-pharmacological interventions, guideline implementation strategies, quality improvement metrics, and patient education.

guidelines•Mar 2026•guidelines

CINV Guideline — Part 3: Recommended Antiemetic Regimens and Special Populations

Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.

guidelines•Mar 2026•guidelines

CINV Guideline — Part 2: Antiemetic Agents — Pharmacology, Dosing, and Adverse Effects

Comprehensive review of antiemetic drug classes used in CINV prophylaxis and treatment: NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, olanzapine, dopamine antagonists, benzodiazepines, and cannabinoids with complete dosing, pharmacokinetics, and adverse effect profiles.

guidelines•Mar 2026•guidelines

CINV Guideline — Part 1: Emetogenic Classification and Risk Factors

Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.

guidelines•Mar 2026•guidelines